Stephen M. Sammut
Senior Fellow, Health Care Management
Boot Camp Co-Chair
Mr. Sammut is Senior Fellow, Health Care Management at the Wharton School. At the Wharton School he teaches venture capital management, corporate development, mergers and acquisitions, biotechnology entrepreneurship, intellectual property strategy, and private equity in emerging markets, and a special seminar on private sector participation in international health.
Mr. Sammut has been involved in the creation or funding of over 40 biotechnology, Internet, and information technology companies globally. He is on numerous Boards of Directors and Advisory Boards including Agora Partners, the Institute for Bioethics, HealthRight International, the Center for Medicine in the Public Interest, and several other organizations. He is also on the editorial board of the Journal of Commercial Biotechnology and Scientific American: New Horizons in Global Health.
His international activity includes coordination of the Wharton School’s Health Care Management program with the Indian School of Business, where he also teaches courses on the Indian Health Care System and Health Care Entrepreneurship. He is also the founder of the Health Care Management MBA Program at Strathmore University in Nairobi, Kenya, the first program of its kind in Africa. He is the founder of the African Institute for Healthcare Management.
Mr. Sammut previously held the positions of Vice President of Development of Teleflex Incorporated where he created and managed acquisitions and alliances, and at S.R. One, Ltd., GlaxoSmithKline’s venture capital fund. He was also Managing Director of Access Partners, a venture fund focused on formation of companies around university technologies and capitalized by corporate strategic investors.
Mr. Sammut is Founder and Chair of the International Institute for Biotechnology Entrepreneurship, a non-profit organization offering intensive training programs throughout the world for managers of biotechnology companies, He actively conducts research on the indigenous capability of emerging market countries to participate in the biotechnology and pharmaceutical industries.